Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 17/20 | 0.72 |
| ▸ | PAK4 | O96013 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174987 | 0.85 | PLK4 (0.55) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL26105438 | 0.84 | PLK4 (1.00) | PLK4PAK4NTRK1 | |
| SCHEMBL30297835 | 0.84 | PLK4 (1.00) | PLK4PAK4NTRK1 | |
| SCHEMBL174456 | 0.82 | PLK4 (0.59) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL22054255 | 0.80 | PLK4 (0.67) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL30297834 | 0.78 | PLK4 (1.00) | PLK4PAK4NTRK1 | |
| SCHEMBL26106093 | 0.78 | PLK4 (1.00) | PLK4PAK4NTRK1 | |
| SCHEMBL174354 | 0.78 | PLK4 (0.50) | PLK4PAK4NTRK1AURKA | |
| SCHEMBL22054995 | 0.76 | PLK4 (0.57) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL28978673 | 0.76 | PLK4 (0.54) | PLK4PAK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PLK4 1763/4885PAK4 143/4885MEN1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.